The race to measure biological aging has produced a problem almost as quickly as it has produced new technology: people are receiving numbers they cannot reliably interpret. DNA methylation tests promise to reveal whether someone is biologically older or younger than their birth certificate suggests. Longevity clinics sell panels of biomarkers, while smartwatches and phone applications offer proprietary scores for readiness, recovery and “pace of aging.” Yet there is no universally accepted scale linking these outputs to specific actions, and two commercial tests can assign the same person dramatically different biological ages. A new perspective published in Biogerontology argues that geroscience needs a public-facing framework comparable to the American Heart Association’s Life’s Essential 8—a simple composite score that could translate complicated aging research into a practical conversation between patients and primary-care clinicians.
The proposal, described by Franco Grimolizzi of the University of Oslo, is not a validated medical test or a claim that aging can be reduced to one definitive number. Instead, it is a blueprint for an “Aging Essential 8,” designed to organize evidence that is already available while acknowledging that major scientific disagreements remain. The suggested instrument would combine four behavioral pillars—diet quality, physical activity, sleep, and avoidance of tobacco and excessive alcohol—with four biological pillars: functional capacity, cognition, cardiometabolic health and one validated estimate of biological age. Each component could be scored from 0 to 100 and averaged into an overall result. The intended purpose would be communication and prevention, not diagnosis, disease labeling or a promise of rejuvenation.
The model takes inspiration from Life’s Essential 8, introduced by the American Heart Association in 2022 to summarize cardiovascular health. That framework scores diet, physical activity, nicotine exposure, sleep, body mass index, blood lipids, blood glucose and blood pressure. Its strength is not that it resolves every question in cardiovascular biology, but that it converts a sprawling risk landscape into a format that people and clinicians can understand. Subsequent evidence has suggested that people with high adherence to the cardiovascular checklist also display markers of slower biological aging, with one American Heart Association report associating strong adherence with a phenotypic age approximately six years younger than that of people with low adherence. Grimolizzi argues that the communication strategy—not necessarily the biological equivalence—could be adapted for aging.
Aging, however, is a much harder target to compress. Cardiovascular risk centers on a comparatively limited set of measurable factors and recognized clinical outcomes. Aging affects every organ system, from immune regulation and metabolism to muscle, cognition and cellular repair, and the rate of decline can differ between tissues in the same individual. There is also no single regulatory diagnosis called “aging” that can serve as the endpoint for a treatment. The field’s influential hallmarks of aging provide a mechanistic vocabulary for researchers, but they were created to organize laboratory knowledge rather than guide a routine clinical consultation. Researchers continue to disagree about whether aging should be understood as one unified process, a collection of interacting processes or something that cannot be captured by a single theory.
Even so, the field has begun to converge on the kinds of measurements that matter. A 2025 expert consensus identified a broad set of candidate outcomes for aging-intervention trials, including insulin-like growth factor 1, growth differentiation factor 15, C-reactive protein, interleukin-6, muscle mass, grip strength, gait speed, balance, the Timed Up and Go test, frailty, cognition, blood pressure and DNA methylation clocks. The panel also concluded that no single biomarker can adequately represent biological aging. That conclusion is crucial: if aging is multidimensional, a composite measure is more plausible than a solitary blood test or epigenetic clock. The unresolved question is not whether multiple measurements are needed, but which ones should be combined, how they should be weighted and how well they predict outcomes across different populations.
The proposed biological-age component is deliberately less exotic than many commercial products. It would use phenotypic age, a measure calculated from routine laboratory results rather than a specialized epigenetic assay. The calculation incorporates nine blood-based variables—albumin, creatinine, glucose, C-reactive protein, lymphocyte percentage, mean corpuscular volume, red-cell distribution width, alkaline phosphatase and white-cell count—alongside chronological age in a published equation. The result estimates the age at which a person’s mortality risk would be average in a reference population. The relevant value is therefore the gap between phenotypic age and actual age, not simply the biological-age estimate itself. A person whose phenotypic age is three years above their chronological age would receive a different score from someone whose estimate is three years below. Importantly, the framework could still operate without this measurement, leaving seven components that require only a questionnaire, a bedside assessment and ordinary blood tests.
In the proposed clinical setting, a general practitioner, practice nurse or community health worker—not necessarily a private longevity clinic—would administer the assessment during routine care. The clinician might record diet and exercise habits, assess sleep and substance exposure, measure blood pressure and laboratory markers, test grip strength or walking speed, and conduct a brief cognitive screen such as the Montreal Cognitive Assessment. The resulting score would be less important than the pattern behind it. A hypothetical 58-year-old with reasonable diet and activity, adequate sleep, no tobacco exposure, preserved gait, a cognitive score of 24, an imperfect cardiometabolic profile and a phenotypic age three years above chronological age might score 63 out of 100. The lowest subscores would identify possible targets for intervention without forcing the patient to decipher an opaque commercial algorithm.
The emphasis on primary care is also an equity argument. Biological-age testing and longevity clinics are currently most accessible to affluent, health-conscious consumers, while the largest deficits in healthy life expectancy often occur in lower-income communities. A tool dependent on expensive sequencing or repeated specialist appointments could widen that gap. By contrast, a framework based mainly on questionnaires, simple functional tests and routine blood work could be used in ordinary healthcare systems, including settings where epigenetic testing is unavailable. The behavioral half may also be especially powerful. In the long-running EPIC-Norfolk study, a combination of not smoking, avoiding physical inactivity, moderate alcohol consumption and a diet consistent with high fruit and vegetable intake was associated with a roughly fourfold difference in all-cause mortality—an effect the investigators estimated to be comparable to 14 years of chronological age. Behavior measures exposure, while biological measures reveal the condition that exposure has produced, making the two halves complementary rather than interchangeable.
The framework remains a proposal, and its uncertainties are substantial. Dietary questionnaires would need to be tested against aging-specific outcomes, and the relative importance of resistance training versus aerobic activity would require clearer validation. Thresholds for the biological-age gap are especially difficult because phenotypic age and DNA methylation clocks are not interchangeable, and their distributions can vary by population and platform. Functional capacity and cognition also change with age, meaning that absolute cutoffs could unfairly penalize healthy older adults. One possible solution is to score walking speed and cognition against age- and sex-specific norms while retaining absolute safety thresholds. Researchers would also need to determine whether all eight components should be averaged equally or weighted according to their predictive power. A consensus panel involving organizations such as the World Health Organization, a national geriatrics society or the American Aging Association could settle these issues through multiround expert review and large-scale cohort analysis. Until then, the Aging Essential 8 should be viewed as a testable starting point—not a finished clinical instrument—but one that could give the public a clearer, more equitable way to understand what longevity science can and cannot yet promise.
Subject of Research: Public-facing composite framework for biological aging, healthy longevity and primary-care risk communication.
Subject of Research: Medicine
Article Title: An aging essential 8: closing the gap between geroscience and the public it serves
Article References: Grimolizzi, F. (2026). An aging essential 8: closing the gap between geroscience and the public it serves. Biogerontology, 27(5), Article 148. https://doi.org/10.1007/s10522-026-10497-y
Image Credits: AI Generated
DOI: 10.1007/s10522-026-10497-y
Keywords: biological aging, aging biomarkers, healthy longevity, composite health score, primary care, geroscience, health equity, biological age testing
Cite this news
APA MLA Chicago
SCIENMAG. (August 28, 2026). Aging Essential 8: Bridging Geroscience and the Public. https://scienmag.com/aging-essential-8-bridging-geroscience-and-the-public/
SCIENMAG. “Aging Essential 8: Bridging Geroscience and the Public.” Scienmag, 28 August 2026, https://scienmag.com/aging-essential-8-bridging-geroscience-and-the-public/. Accessed 28 August 2026.
SCIENMAG. “Aging Essential 8: Bridging Geroscience and the Public.” Scienmag. August 28, 2026. https://scienmag.com/aging-essential-8-bridging-geroscience-and-the-public/
Copy citation Download RIS
Tags: aging biomarkersAging Essential 8aging research translationaging score standardizationaging-related health interventionsbiological age interpretationbiological age vs chronological agebiological aging measurementDNA methylation aging testsgeroscience communicationgeroscience public frameworkhealth behavior and aginglifestyle factors and aginglongevity clinicspersonalized aging assessmentpersonalized aging interventionspractical aging assessmentpublic health aging framework
